A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1982 • 10,605 citations

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1996 • 1,584 citations

Analysis of survival by tumor response.

1983 • 1,021 citations

Analysis of survival by tumor response.

1986 • 1,018 citations

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

1999 • 994 citations

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

1999 • 907 citations

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

1993 • 400 citations

Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone

1999 • 229 citations

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

1998 • 223 citations

Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer

1999 • 169 citations

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.

1995 • 101 citations

Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate Cancer

1996 • 97 citations

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials.

1998 • 53 citations

Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor

1999 • 35 citations

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer

1992 • 30 citations